Spinal cord injury with unilateral versus bilateral primary hemorrhage - Effects of glibenclamide

► Glibenclamide (GLIB) is an emerging pharmacotherapy in spinal cord injury (SCI). ► In SCI, an impact force delivered laterally causes unilateral primary hemorrhage. ► Medially, the same force causes bilateral hemorrhage and 45% larger lesions. ► GLIB was highly beneficial with both unilateral and bilateral primary hemorrhage. ► The magnitude of benefit from GLIB depended on the extent of primary hemorrhage.